Literature DB >> 1360156

Kinetics and mechanism of degradation of a cyclic hexapeptide (somatostatin analogue) in aqueous solution.

R Krishnamoorthy1, A K Mitra.   

Abstract

A highly active cyclic hexapeptide analogue of somatostatin, Cyclo(N-Me-L-Ala-L-Tyr-D-Trp-L-Lys-L-Val-L-Phe), L-363,586, was found to improve the control of postprandial hyperglycemia in diabetic animals when given in combination with insulin. The compound is reported to be relatively stable in blood, nasal cavity, and intestinal lumen but undergoes rapid degradation in aqueous solution. The objective of this study was to elucidate the degradation mechanisms based on the kinetic data and the structure of the degradation products. Both pH and temperature had a profound influence on the instability of the peptide in aqueous solution. The data indicated that the peptide was most stable at a pH of about 4.7. The pH-rate profile exhibited specific acid catalysis at a pH less than 3.0 and base catalysis above pH 10.5. The kinetic pKa was determined to be 9.7. This pKa could be attributed to the tyrosine residue. The mechanisms of degradation under acidic and alkaline conditions appear to be different. Identification of the fragments obtained using mass spectrometry and amino acid sequencing suggest that the cyclic compound was cleaved to yield a linear fragment, which underwent further cleavage at both peptide linkages alpha to the tryptophanyl residue. The indole group of that residue is probably the potential nucleophile attacking the adjacent carbonyls. A rate equation for the degradation of the hexapeptide has been proposed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360156     DOI: 10.1023/a:1015813619192

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

Review 1.  Stability of protein pharmaceuticals.

Authors:  M C Manning; K Patel; R T Borchardt
Journal:  Pharm Res       Date:  1989-11       Impact factor: 4.200

2.  Conformationally restricted bicyclic analogs of somatostatin.

Authors:  D F Veber; F W Holly; W J Paleveda; R F Nutt; S J Bergstrand; M Torchiana; M S Glitzer; R Saperstein; R Hirschmann
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

3.  Clinical evaluation of somatostatin as a potential ajunct to insulin in the management of diabetes mellitus.

Authors:  J E Gerich; T A Schultz; S B Lewis; J H Karam
Journal:  Diabetologia       Date:  1977-09       Impact factor: 10.122

4.  A potent cyclic hexapeptide analogue of somatostatin.

Authors:  D F Veber; R M Freidlinger; D S Perlow; W J Paleveda; F W Holly; R G Strachan; R F Nutt; B H Arison; C Homnick; W C Randall; M S Glitzer; R Saperstein; R Hirschmann
Journal:  Nature       Date:  1981-07-02       Impact factor: 49.962

5.  Chemical pathways of peptide degradation. II. Kinetics of deamidation of an asparaginyl residue in a model hexapeptide.

Authors:  K Patel; R T Borchardt
Journal:  Pharm Res       Date:  1990-07       Impact factor: 4.200

6.  Somatostatin modulation of glucagon secretion and its importance in human glucose homeostasis.

Authors:  J E Gerich
Journal:  Metabolism       Date:  1978-09       Impact factor: 8.694

Review 7.  Glucagon physiology and pathophysiology.

Authors:  R H Unger
Journal:  N Engl J Med       Date:  1971-08-19       Impact factor: 91.245

8.  A super active cyclic hexapeptide analog of somatostatin.

Authors:  D F Veber; R Saperstein; R F Nutt; R M Freidinger; S F Brady; P Curley; D S Perlow; W J Paleveda; C D Colton; A G Zacchei
Journal:  Life Sci       Date:  1984-04-02       Impact factor: 5.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.